Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06653842
PHASE2

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

Sponsor: Palvella Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2024-12-20

Completion Date

2026-03

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

QTORIN 3.9% rapamycin anhydrous gel

QTORIN 3.9% Rapamycin Anhydrous Gel

Locations (10)

Children's Hospital of Orange County

Irvine, California, United States

Stanford University

Palo Alto, California, United States

Colorado Children's Hospital

Aurora, Colorado, United States

Johns Hopkins

Baltimore, Maryland, United States

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University of Utah Health

Salt Lake City, Utah, United States